Cue Biopharma, Inc. Operating Lease Cost
Cue Biopharma, Inc. (CUE) reported Operating Lease Cost of $853.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2023-11-03
- Cue Biopharma, Inc. operating lease, cost for the quarter ending 2023-09-30 was $853.00K, a 0.81% decline year-over-year.
- Cue Biopharma, Inc. operating lease, cost for the quarter ending 2023-06-30 was $857.00K, a 22.44% decline year-over-year.
- Cue Biopharma, Inc. operating lease, cost for the quarter ending 2023-03-31 was $145.00K, a 0.00% change year-over-year.
- Cue Biopharma, Inc. operating lease, cost for the quarter ending 2022-09-30 was $860.00K, a 29.80% decline year-over-year.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month |
|---|---|---|---|---|
| 2023-09-30 | $853.00K 10-Q · filed 2023-11-03 | $1.71M derived: sum of 2 quarters · filed 2023-11-03 | $2.57M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $857.00K 10-Q · filed 2023-08-08 | $1.71M 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | $145.00K 10-Q · filed 2023-05-09 | |||
| 2022-09-30 | $860.00K 10-Q · filed 2022-11-14 | $1.97M derived: sum of 2 quarters · filed 2022-11-14 | $3.31M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.10M 10-Q · filed 2022-08-04 | $2.44M 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $145.00K 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | $1.23M 10-Q · filed 2021-11-09 | $2.45M derived: sum of 2 quarters · filed 2021-11-09 | $3.67M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $1.23M 10-Q · filed 2021-08-09 | $2.44M 10-Q · filed 2021-08-09 | ||
| 2020-09-30 | $1.21M 10-Q · filed 2020-11-09 | $2.29M derived: sum of 2 quarters · filed 2020-11-09 | $3.37M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $1.08M 10-Q · filed 2020-08-07 | $2.16M 10-Q · filed 2020-08-07 | ||
| 2020-03-31 | $1.22M 10-Q · filed 2021-05-10 | $1.08M 10-Q · filed 2020-05-07 | ||
| 2019-09-30 | $1.14M 10-Q · filed 2019-11-07 | $3.41M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |